指南与共识系统性红斑狼疮

系统性红斑狼疮的管理:支持2023年EULAR推荐更新的系统文献综述

Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations.
指南 / 共识 · Ann Rheum Dis · 2024-10-21

本系统文献综述检索2018年1月1日至2022年12月31日Medline与Cochrane Library文献,分析SLE管理新证据以支持2023年EULAR推荐更新。共纳入439篇相关文献,多数为低或中等质量观察性研究;高质量RCT证实阿尼鲁单抗、贝利尤单抗与伏环孢素在相应人群中的疗效,并发现达标治疗与长期良好结局相关。

要点

  • 高质量RCT证实阿尼鲁单抗对非肾脏SLE、贝利尤单抗与伏环孢素对狼疮肾炎的疗效优于标准治疗。
  • 多项观察性研究证实达到临床缓解或低疾病活动度可降低多种不良结局风险。
  • 两项RCT发现停用糖皮质激素或免疫抑制剂者复发率更高,但观察性队列提示部分患者撤药可能可行。

核心结论

  • 阿尼鲁单抗与贝利尤单抗在肾外SLE中较标准治疗实现更好的疾病控制,贝利尤单抗联合伏环孢素在狼疮肾炎高质量RCT中获得更高应答率。
  • 缓解与低疾病活动度与良好长期结局相关。
  • 达到上述目标的患者,糖皮质激素与免疫抑制治疗可逐渐减量。

研究设计与样本

  • 按照EULAR标准化操作流程,在Medline与Cochrane Library数据库进行系统文献综述,纳入2018年1月1日至2022年12月31日发表的文献。
  • 研究问题聚焦五个领域:SLE治疗的获益与危害、达到缓解或低疾病活动度的获益、减量或撤药的风险与获益、合并抗磷脂综合征的SLE管理、水痘-带状疱疹病毒与SARS-CoV2免疫接种的安全性。
  • 采用人群、干预、对照与结局框架为每个研究主题制定检索策略。

主要发现

  • 共识别439篇相关文献,多数为低或中等质量的观察性研究。
  • 高质量RCT证实1型干扰素受体抑制剂阿尼鲁单抗在非肾脏SLE中的疗效,以及贝利尤单抗与新型钙调神经磷酸酶抑制剂伏环孢素在狼疮肾炎中较标准治疗的疗效。
  • 对于狼疮肾炎以外的特定器官表现治疗,缺乏高质量数据。
  • 多项观察性研究证实达到临床缓解或低疾病活动度可降低多种不良结局风险。
  • 两项存在一定偏倚风险担忧的随机试验分别发现,SLE与狼疮肾炎患者停用糖皮质激素或免疫抑制剂后复发率更高,而观察性队列研究提示部分患者撤药可能可行。

关键数值与推荐

  • 阿尼鲁单抗在非肾脏SLE中较标准治疗实现更好的疾病控制。
  • 贝利尤单抗与伏环孢素联合治疗在狼疮肾炎高质量RCT中获得更高应答率。
  • 缓解与低疾病活动度与良好长期结局相关。
  • 达到缓解或低疾病活动度目标者,糖皮质激素与免疫抑制治疗可逐渐减量。

临床怎么用

  • 作者认为,达到缓解或低疾病活动度目标的患者,糖皮质激素与免疫抑制治疗可逐渐减量。
  • 作者指出,狼疮肾炎以外的特定器官表现治疗缺乏高质量数据。

局限性

  • 多数纳入文献为低或中等质量的观察性研究。
  • 狼疮肾炎以外的特定器官表现治疗缺乏高质量数据。
  • 两项随机试验存在一定偏倚风险担忧。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analyse the new evidence (2018-2022) for the management of systemic lupus erythematosus (SLE) to inform the 2023 update of the European League Against Rheumatism (EULAR) recommendations. METHODS: Systematic literature reviews were performed in the Medline and the Cochrane Library databases capturing publications from 1 January 2018 through 31 December 2022, according to the EULAR standardised operating procedures. The research questions focused on five different domains, namely the benefit/harm of SLE treatments, the benefits from the attainment of remission/low disease activity, the risk/benefit from treatment tapering/withdrawal, the management of SLE with antiphospholipid syndrome and the safety of immunisations against varicella zoster virus and SARS-CoV2 infection. A Population, Intervention, Comparison and Outcome framework was used to develop search strings for each research topic. RESULTS: We identified 439 relevant articles, the majority being observational studies of low or moderate quality. High-quality randomised controlled trials (RCTs) documented the efficacy of the type 1 interferon receptor inhibitor, anifrolumab, in non-renal SLE, and belimumab and voclosporin, a novel calcineurin inhibitor, in lupus nephritis (LN), when compared with standard of care. For the treatment of specific organ manifestations outside LN, a lack of high-quality data was documented. Multiple observational studies confirmed the beneficial effects of attaining clinical remission or low disease activity, reducing the risk for multiple adverse outcomes. Two randomised trials with some concerns regarding risk of bias found higher rates of relapse in patients who discontinued glucocorticoids (GC) or immunosuppressants in SLE and LN, respectively, yet observational cohort studies suggest that treatment withdrawal might be feasible in a subset of patients. CONCLUSION: Anifrolumab and belimumab achieve better disease control than standard of care in extrarenal SLE, while combination therapies with belimumab and voclosporin attained higher response rates in high-quality RCTs in LN. Remission and low disease activity are associated with favourable long-term outcomes. In patients achieving these targets, GC and immunosuppressive therapy may gradually be tapered. Cite Now.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kostopoulou M, Mukhtyar CB, Bertsias G, et al. Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations. Ann Rheum Dis. 2024. PMID: 38777375. doi:10.1136/ard-2023-225319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。